These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21179900)

  • 1. [Clinical rationale for using dabigatran etexilate in the complex treatment of venous thromboembolism].
    Sukovatykh BS; Savchuk OF
    Khirurgiia (Mosk); 2010; (10):78-82. PubMed ID: 21179900
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
    Schulman S; Kearon C; Kakkar AK; Mismetti P; Schellong S; Eriksson H; Baanstra D; Schnee J; Goldhaber SZ;
    N Engl J Med; 2009 Dec; 361(24):2342-52. PubMed ID: 19966341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

  • 4. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
    Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
    Prandoni P; Taher A
    Expert Opin Pharmacother; 2010 Apr; 11(6):1035-7. PubMed ID: 20307227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study].
    Liakishev AA
    Kardiologiia; 2010; 50(3):80-1. PubMed ID: 20459411
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Feb; 135(6):256-9. PubMed ID: 20104442
    [No Abstract]   [Full Text] [Related]  

  • 9. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemopericardium in a patient treated with dabigatran etexilate.
    Barton CA; McMillian WD; Raza SS; Keller RE
    Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
    ; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
    J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rash associated with dabigatran etexilate.
    To K; Reynolds C; Spinler SA
    Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate: management in acute ischemic stroke.
    Javedani PP; Horowitz BZ; Clark WM; Lutsep HL
    Am J Crit Care; 2013 Mar; 22(2):169-76. PubMed ID: 23455868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
    Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
    Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa).
    Cardiovasc J Afr; 2010; 21(3):173-4. PubMed ID: 20532462
    [No Abstract]   [Full Text] [Related]  

  • 18. Dabigatran etexilate for venous thromboembolism: a safety evaluation.
    Brown R; Lip GY; Gallego P
    Expert Opin Drug Saf; 2014 May; 13(5):639-47. PubMed ID: 24598005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate.
    Eriksson BI; Smith H; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Jul; 7(7):557-8. PubMed ID: 18591978
    [No Abstract]   [Full Text] [Related]  

  • 20. Dabigatran versus enoxaparin after total hip replacement.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Dec; 370(9604):2002-3; author reply 2003-4. PubMed ID: 18083399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.